444 results about "Disease risk" patented technology

Methods and apparatus are provided for determining individual responses to induced and actual mental stress and for identifying individuals susceptible to detrimental effects of mental stress on the cardiovascular system. The subjects may be at risk for chronic effects of mental stress by virtue of synergistic effects of mental stress and cardiovascular (CV) disease risk factors) or may be at risk, or vulnerable to, acute effects of mental stress by virtue of synergistic effects of mental stress and underlying hidden coronary atherosclerosis. The invention further provides methods and apparatus for assessing vascular reactivity in individuals under ambulatory conditions and relating mental stress responses to vascular reactivity.

Methods for determining statistical models for predicting disease risks of a population are provided. Two types of data associated with members of the population are collected. The data may include both genetic and non-genetic types of data. A candidate statistical model is selected for calculating the disease risk. The model has a plurality of parameters and is a function of only one of the two types of data. A data weight is determined for each member of the population. Members having like data of the other type have like weights. The parameters of the model are optimized by fitting the collected data to the model taking into account of the weights.

The invention provides a method and a system for predicting cardiovascular and cerebrovascular disease risks. The method comprises the following steps: step 1, defining problems of cardiovascular and cerebrovascular disease prognosis risk prediction, step 2, collecting health medical data of cardiovascular and cerebrovascular disease patients; step 3, preprocessing data, including data integration, data cleaning, and processing missing data; step 4, constructing features and selecting features, identifying potential risk factors; step 5, the identified risk factors and rehabilitation outcomes forming an input-output sample set, inputting the input-output sample set to a random forest algorithm for model training, and evaluating prediction performance of a model. The method and the system can obtain health medical data of cardiovascular and cerebrovascular disease patients, the data being required by a clinician input model, and a predicted rehabilitation outcome of a patient in a certain time period in future is obtained through the model. The method and the system can preferably predict prognosis risks, so as to realize personalized accurate rehabilitation treatment.

The use of a medical software platform to collect, normalize, and aggregate clinical data. Supports clinical care and provides research and clinical tools for institutions, healthcare providers, researchers, and patients. The invention provides a graphical interface to customize searches in the database for specified subsets of conditions, treatments or outcomes. The invention also provides a system and method for searching through clinical databases for desired terms which may provide additional information to a physician regarding patient care. Furthermore, this invention facilitates personalized medicine-based practices as relationships between genetics, personal heath data from multiple sources, disease risk and drug response can be more easily visualized and utilized for patient care and research.

A method and system use a combined contribution of multiple disease risk factors to predict the risk of onset of particular diseases in an individual. The prediction models use information from separate studies. Multiple disease predictions for a predetermined number of diseases are made. The predictions are used to calculate the individual's mortality risk and life expectancy. The life expectancy is compared to that of age and gender matched peers to determine the inner age of the individual.

The invention relates to methods and biomarkers for assessing a subject's risk for a disease, such as cancer, an autoimmune disease or a neurological disease. In particular, the invention provides methods and biomarkers for creating exon copy number variation (ECNV) profiles, and determining disease risk according to the subject's ECNV profiles.

The invention discloses a health management system and implementation method thereof, belonging to the technical field of disease prevention and control. The health management system comprises a computer application module, a special testing module and a health management module. The computer application module comprises a user information acquisition module, a health risk assessment module and a disease risk assessment module. The health management repertoire includes the following steps: setting up a health risk assessment database in the health risk assessment module; and setting up a disease risk assessment database in the disease risk assessment module. The health management system and the implementation method thereof have the advantages that through the health management repertoire, the risk of an individual getting certain specific chronic disease or the outcome of the disease in the future can be simply estimated, thus helping the individual to have a fuller and more comprehensive understanding about the risk and the gravity of the threat of the disease so that the individual can take comprehensive intervention against a specific cause or high-risk factor of the disease to prevent and reverse the progress of the disease. Therefore, the health management system and the implementation method can alleviate the living and economic burdens of the families and the society.

Compositions are provided that include water soluble or water dispersible film shreds, a carrier and an active, such as, but not limited to a drug, flavoring agent or coloring agent. Also provided are methods of use of the film shreds, such as in improving the dissolution, stability, aesthetics, or taste of a composition or its components, and in reducing a disease risk associated with an active.

The invention relates to a health risk assessment and disease early warning information system, and belongs to the technical field of health management. The system comprises an employee health management system and a personal health system; the employee health management system comprises 11 modules such as an employee basic information management module, an employee health data acquisition module,and an employee health questionnaire management module; the personal health system consists of an ordinary user registration sub-module, a personal information management sub-module, a personal health history management sub-module, a daily health monitoring sub-module, a medical sick rest management sub-module, a health questionnaire sub-module, an annual health examination sub-module, a health condition assessment sub-module, a disease risk assessment sub-module, a health promotion management sub-module, and a health consultation forum sub-module. The health risk assessment and disease earlywarning information system forms an integrated network management mode of health management, health risk assessment and health risk intervention control.

Provided are methods for determining concurrently with a simple, minimally invasive test, the adequacy of pancreatic beta-cell compensation and / or the presence of tissue insulin resistance in a subject human or an experimental animal. The methods allow for the determination of a subject's or experimental animal's susceptibility to developing type 2 diabetes mellitus (DM2) or to progression to more advanced forms of DM2. Among other uses, the methods allow for diagnostic classification of subjects for decisions regarding therapeutic interventions, clinical differentiation between type 1 DM and DM2, clinical monitoring of treatments intended to reduce risk of developing DM2 in non-diabetic subjects, clinical monitoring of agents intended to improve existing DM2 and to prevent progression of DM2, clinical development and testing of new compounds, candidate agents, or candidate therapies for preventing progression to DM2 or disease progression in existing DM2, and preclinical screening of candidate agents or candidate therapies in experimental animals to identify and characterize agents having insulin-sensitizing properties, pancreatic stimulatory or regenerative properties or other desirable actions.

A medical diagnostic method and instrumentation system for analyzing noncovalently bonded agglomerated biological particles is described. The method and system comprises: a method of preparation for the biological particles; an electrospray generator; an alpha particle radiation source; a differential mobility analyzer; a particle counter; and data acquisition and analysis means. The medical device is useful for the assessment of human diseases, such as cardiac disease risk and hyperlipidemia, by rapid quantitative analysis of lipoprotein fraction densities. Initially, purification procedures are described to reduce an initial blood sample to an analytical input to the instrument. The measured sizes from the analytical sample are correlated with densities, resulting in a spectrum of lipoprotein densities. The lipoprotein density distribution can then be used to characterize cardiac and other lipid-related health risks.

The invention relates to a big data health prediction system. The system comprises a data information collection module, a big data analysis platform and an intelligent terminal, wherein the data information collection module is used for collecting user health feature data information; the big data analysis platform builds a disease risk prediction model with high accuracy by utilizing a machine learning method, performs prediction and disease risk assessment on a health state of a user according to the built disease risk prediction model, and gives guiding views of the health state of the user; the intelligent terminal is used for receiving a final disease prediction result and the guiding views of the health state of the user obtained by the big data analysis platform; and the user can upload the health feature data information to the big data analysis platform through the intelligent terminal in real time. The user can prevent own health problems according to the guiding views of the health state of the user, thereby guaranteeing health of the user; and the system is relatively high in practicality and high in accuracy.

A dietary supplement is created, comprised of material from the following nutrients, vitamins, herbs, minerals, and food and plant substances and food and plant derivatives: lycopene, vitamin E, selenium, green tea, coenzyme Q10, garlic, folic acid, vitamin C, curcumin, seaweed, Cordyceps sinsensis mushroom, Lentinus edodes (shiitake) mushroom, and Ganoderma lucidum (reishi) mushroom. The composition is administered orally for individuals who wish to reduce their risk of disease, particularly cancer-risk.

A disease risk evaluation and education tool, preferably implemented in logic on a computing device such as a Personal Digital Assistant, permits a user to input patient-specific data relevant to evaluating that patient's risk for a particular disease, e.g., coronary heart disease. The tool's logic calculates the equivalent age of the patient, based on the Framingham data set and on the input data, and presents one or more treatment recommendations.

The present invention is directed to prognostic and diagnostic methods to assess lung disease risk caused by airway pollutants by analyzing expression of one or more genes belonging to the airway transcriptome provided herein. Based on the finding of a so called “field defect” affecting the airways, the invention further provides a minimally invasive sample procurement method in combination with the gene expression-based tools for the diagnosis and prognosis of diseases of the lung, particularly diagnosis and prognosis of lung cancer.

The present invention uses spectroscopic tissue volume measurements using non-ionizing radiation to detect pre-disease transformations in the tissue, which increase the risk for this disease in mammals. The method comprises illuminating a volume of selected tissue of a mammal with light having wavelengths covering a pre-selected spectral range, detecting light transmitted through, or reflected from, the volume of selected tissue, and obtaining a spectrum of the detected light. The spectrum of detected light is then represented by one or more basis spectral components, an error term, and an associated scalar coefficient for each of the basis spectral components. The associated scalar coefficient is calculated by minimizing the error term. The associated scalar coefficient of the each of the basis spectral components is correlated with a pre-selected property of the selected tissue known to be indicative of susceptibility of the tissue for the pre-selected disease to obtain the susceptibility for the mammal to developing the pre-selected disease.

The invention relates to a clinic remote service system based on artificial intelligence. The system comprises the components of a clinic terminal, a cloud server, a patient terminal, a doctor terminal, a self-service medicine selling terminal, a medicine selling user terminal and a commodity supplementing terminal. The clinic terminal, the patient terminal, the doctor terminal, the self-service medicine selling terminal, the medicine selling user terminal, the commodity supplementing terminal and the cloud server perform data transmission through a network. The clinic remote service system has advantages of establishing a novel medical service system, settling problems of preliminary diagnosis and treatment and health management of a patient, realizing a one-station medical health preserving solution which comprises medical health examination, AI disease diagnosis, inquiry consultation, electronic medicine commerce, chronic disease management, saving diagnosis time and diagnosis cost,and reducing disease risk.

The present invention provides systems and method for constructing classifiers that distinguish between trait subgroups using molecular marker data from blood samples. The invention further encompasses the use of the classifiers and combinations of molecular markers identified by the classifiers in a wide variety of applications including: diagnosis; prognosis; prediction of disease, stage of disease or disease risk; monitoring disease progression and / or regression; monitoring disease reoccurrence and identifying risk of disease reoccurrence; determining and / or predicting response to treatment and / or treatment outcomes; monitoring and / or predicting treatment compliance or non compliance and the like. The invention further provides a variety of selected molecular markers and a means to identify combinations of the selected molecular markers useful for diagnosing particular traits of interest.

The invention relates to a disease risk predication method and system. The method comprises the following steps of: S1, receiving input gene sequencing result information; analyzing the input gene sequencing result information to obtain all mutant gene information; S2, looking up disease gene mutant information of corresponding gene sites from a precision medical knowledge base according to the gene sites corresponding to the mutant gene information, so as to obtain at least one piece of disease gene mutant information; S3, matching each piece of the disease gene mutant information with all the disease gene mutant information to obtain the similarity of each piece of the mutant gene information, and all the disease gene mutant information; and S4, obtaining a risk predication table aiming at the gene sequencing result information according to the similarity of each piece of the mutant gene information, and all the disease gene mutant information. By analyzing an association relation of susceptibility genes, mutation sites, mutation types and diseases, disease risk predication is carried out on healthy people and general disease risk grade predication is provided; disease risks in the future are reduced.

The present invention discloses a disease risk assessment and personalized health report generation system and method. The method comprises: inputting longitudinal health examination big data; arranging the data; defining the threshold range of various indicators of the disease according to the name of the disease, and using the sas software to establish a corresponding disease queue according to the threshold range of various indicators of the disease; and after establishing the queue, using the cox single factor regression analysis method to carry out variable selection on each variable; carrying out multi-factor regression analysis on the variables incorporated into the cox regression model; establishing a cox proportional risk model; verifying the inside of the cox proportional risk mode, and verifying the outside of the cox proportional risk model; obtaining a disease prediction model; generating a disease risk assessment hyperbola; inputting new individual physical examination indicators, generating disease risk assessment results according to the disease prediction model and the disease risk assessment hyperbola, and outputting a disease risk assessment and personalized health report according to the preset indicators.

Indole-3-propionic acid as a marker and for treatment for Huntington Disease.

The disclosure provides methods and systems for assessing microsatellites, for identifying informative microsatellite loci, and for using microsatellite data. Microsatellite information has numerous uses including, for example, to characterize disease risk, to predict responsiveness to therapy, and to non-invasively diagnose subjects.

The present invention relates generally to a peripheral marker or marker of blood brain barrier integrity and methods of using them in the diagnosis, prognosis, and treatment of a variety of diseases. The preferred embodiments of the present invention relate to methods, compositions, kits, and assays useful in determining the integrity or permeability of a blood brain barrier. The various embodiments of the present invention can be used to identify subjects at risk for developing a disease associated with increased permeability of the blood brain barrier, as well as to provide insight on the ability of an agent or agents to pass the blood brain barrier. Preferably, increased levels of S100β protein are used alone or in combination with other markers of diseased state in order to diagnose and prognosticate permeability of the BBB.

The invention relates to a cardiac disease risk pre-warning system and method based on a deep learning algorithm. According to early-stage preparation, a normal electrocardiogram signal and electrocardiogram signals of various cardiac diseases are obtained clinically, the signals are segmented, the frequency rhythm information of the signals is extracted through the wavelet analysis algorithm, the obtained frequency rhythm information is transmitted into a deep learning framework in a classified mode, training is conducted, and various trained deep learning models are obtained. According to later-stage application, a user wears an electrocardiogram data acquisition device capable of carrying out data transmission, the acquired electrocardiogram signals are uploaded to a server, the server extracts the frequency rhythm information of the signals, and transmits the frequency rhythm information into the trained deep learning model of the frequency rhythm of the normal electrocardiogram signal at first for discrimination, if cardiac disease symptoms exist, the frequency rhythm information of the electrocardiogram signals is transmitted into the trained deep learning models of the various cardiac diseases in sequence for screening and evaluating, and a report about the risk of the cardiac disease of a specific class is fed back to a user.

Systems, methods and a software product for disease reduction education and risk assessment are disclosed. In one embodiment, a system for computer-assisted disease risk assessment and education includes a processor that generates at least a plurality of questions directed to a disease risk assessment for a user. Based upon responses received from a user, the processor is further operable to generate one or more plans configured to prospectively guide the risk behavior and sexual activity of the user. At least one personal data entry and display device (PDDA) is communicatively coupled to the processor, that is operable to at least display the plurality of questions and to accept corresponding responses from the user.

The invention discloses an antibiotic-free feed for fattening-stage pigs. The antibiotic-free feed for the fattening-stage pigs comprises the following components in parts by weight: 40-50 parts of corns, 20-25 parts of barley, 17-20 parts of bean meal, 8-12 parts of whole rice bran, 6-8 parts of an organic compound acidifying agent, 2-5 parts of imported corn DDGS, 0.3-0.4 part of table salt, 1-1.5 parts of stone powder, 0.3-0.5 part of calcium hydrogen phosphate, 0.3-0.5 part of amino acid, 0.05-0.1 part of choline chloride, 0.03-0.1 part of a compound micro-ecological preparation, 0.02-0.05 part of an antioxidant, 0.03-0.04 part of vitamin premix, 0.1-0.15 part of organic mineral premix, 0.002-0.005 part of a compound enzyme preparation, 0.02-0.05 part of high-temperature-resistant phytase, 0.004-0.01 part of plant essence oil, 0.15-0.2 part of yeast cell walls, 0.01-0.03 part of an antioxidant, 0.02-0.05 part of an anti-mildew agent and 0.02-0.05 part of zeolite powder. The invention solves the problems of drug residues, drug resistance and environmental pollution caused by addition of the antibiotics in the feed. Moreover, the acidifying agent, the organic trace elements, the yeast cell walls and the plant essence oil are added into the feed, so that the feed has the effects of improving pig immunity and reducing disease risks of animals compared with antibiotic-containing feeds; and the feed is capable of improving production performance and meat qualities of the pigs.

Systems and methods for identifying genetic variations in a disease and diagnosing a patient with a mental illness, or a generic variant of same. The systems and methods use genomics and phenomics in a computer-implemented methods to identify biclusters in phenomic and genomic data, discover relationships among the biclusters, organize the relations into partitions, rank the predictive utility of features, and map the disease risk function. This can in turn be used to diagnose a patient in a person-centered fashion.

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and / or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.

A technique of using collaborative family medical history (CFMH) to estimate disease risk includes establishing CFMH information of a user and a plurality of relatives of the user, the CFMH information including genetic information of at least some of the family members, genetic information of the user, or both. It further includes analyzing the CFMH information, including the genetic information. It further includes determining a potential risk condition of the user and a potential risk condition of at least a family member based on the CFMH information. It also includes outputting the potential risk condition of the user and the potential risk condition of the at least one family member.

This invention features our discovery on usages of Methylenetetrahydrofolate Reductase (MTHFR) gene polymorphisms in predicting homocysteine (Hcy) level and / or incidence and prognosis of diseases associated with increased Hcy level in a subject, as well as predicting treatment effects of medicines in the category of Angiotension Converting Enzyme Inhibihor (ACEI) with and without combination with B Vitamins. This invention also features our discovery on laboratory and analytical methods that are essential to the above described usages of MTHFR gene polymorphisms. In addition, this invention features a kit that has translated the above discoveries into a practical and reliable tool that can be applied to accomplish the above described usages of MTHFR gene polymorphisms. This invention represents an important step in realizing personalized medicine, with the goal to tailor diagnosis, prevention and treatment strategy to meet individual needs.